HMPL-A251

PreclinicalSmall molecule

HHutchmed

HMPL-A251 is one of 4 small molecule programs targeting Solid Tumors, Adult. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid Tumors, AdultRecruiting

Solid Tumors, AdultPreclinical

Recruiting

Competition

Competitive Landscape

3 competitors in Solid Tumors, Adult

#DrugCompanyPhaseTrials

GC203 TIL

SShanghai Juncell Therapeutics

Phase 1

1 2

GT101

GGrit Biotechnology

Phase 1

1 3

HMPL-A580

HHutchmed

Preclinical

1 4

HMPL-A251

HHutchmed

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

PreclinicalRecruiting

Solid Tumors, Adult

NCT07228247

Clinical

Trials by Indication[1]

Solid Tumors, Adult1 trial

A Phase Ⅰ/Ⅱa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HMPL-A251 in Participants With Advanced or Metastatic HER2-Expressing Solid Tumors

Recruiting·HHutchmed·Preclinical·NCT07228247·147 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HMPL-A251. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HMPL-A251 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HMPL-A251. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hutchmed company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHutchmed

HMPL-A251

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Solid Tumors, Adult1 trial

References

Drug Info

Quick Facts

Related News